Valuation: Neuralstem, Inc.

Market Cap 373M 322M 302M 275M 517M 35.66B 524M 3.54B 1.39B 17.86B 1.4B 1.37B 59.43B P/E 2026 *
-9.51x
P/E 2027 * -7.75x
Enterprise Value 275M 238M 223M 203M 382M 26.32B 387M 2.61B 1.02B 13.18B 1.03B 1.01B 43.86B EV / Sales 2026 *
771x
EV / Sales 2027 * -
Free-Float
-
Yield 2026 *
-
Yield 2027 * -

Financials

2026 *2027 *
Net sales 357K 308K 289K 263K 495K 34.15M 502K 3.39M 1.33M 17.11M 1.34M 1.31M 56.91M -
Net income -47.86M -41.32M -38.76M -35.31M -66.39M -4.58B -67.31M -454M -178M -2.29B -180M -176M -7.63B -63.05M -54.43M -51.06M -46.51M -87.45M -6.03B -88.66M -599M -235M -3.02B -237M -232M -10.05B
Net Debt -97.7M -84.34M -79.13M -72.07M -136M -9.34B -137M -928M -363M -4.68B -367M -359M -15.57B -335M -289M -271M -247M -464M -32B -471M -3.18B -1.25B -16.03B -1.26B -1.23B -53.33B
Logo Neuralstem, Inc.
Seneca Biopharma, Inc., formerly Neuralstem, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing treatments for diseases of unmet medical need. It is focused on finding and acquiring new assets, sciences and technologies that provide therapies for patients. It intends to focus on developing a pipeline of biopharmaceuticals and commercializing those products.
Employees
-
Sector
-